Abstract:Background: Although many approaches based either on molecular investigations or on deep-learning algorithms applied to tissue sections have been proposed to stratify colorectal cancers (CRC) patients, clinical implementation of these novel cost-and time-consuming techniques is lacking, and conventional tumor-node-metastasis (TNM) staging remains one of the key factors to determine patient's treatment. Hence, we developed a novel and solely Haematoxylin and Eosin (H&E) based histopathologic prognostic biomarker, called SARIFA (Stroma AReactive Invasion Front Areas, i.e., direct contact between tumor cells and fat cells). Materials/Methods: Based on a previous study, in which we could show that gene-expression based computational drug response prediction (oncoPredict) indicates a SARIFA-dependent differential drug sensitivity, we investigated whether SARIFA-status can predict which CRC patients might benefit from adjuvant therapy. SARIFA-status was established for 1,727 CRC patients from the prospective Netherlands Cohort Study. Multivariate-adjusted Cox regression analysis was performed (median follow-up: 4.79 years, with 1,463 deaths being observed in the first 10 years of follow-up [933, 63.8%, were CRC-related]). Only stages II to IV were included for further analysis regarding differential treatment response (n = 1,384). Results: In Multivariate-adjusted Cox regression analysis including patient age, sex, tumor location, pTNM stage, grade of differentiation, and mismatch repair status, SARIFA-positive CRC patients (n=496) benefitted significantly from adjuvant therapy (HRCRC-specific 0.59; 95% CI 0.44-0.78) compared to SARIFA-positive patients treated with surgery alone, which was not significant for SARIFA-negative CRC patients (HRCRC-specific 0.88; 95% CI 0.68-1.15). Regarding overall survival (OS), adjuvant therapy led to better OS outcomes regardless of SARIFA-status (HRoverall all patients 0.74; 95% CI 0.62-0.87). Conclusion: Our results suggest that SARIFA-positivity predicts a CRC-specific survival benefit from adjuvant therapy. As SARIFA-positivity is closely linked to an upregulation of lipid metabolism and an altered immune response, further studies are warranted to explore the potential benefit of not only conventional chemotherapy but also immunotherapy, targeted therapy as well novel drugs targeting lipid-metabolism. As SARIFA-status can be assessed fast and easily on for every cancer patient available H&E slides, SARIFA-status could serve as an ideal biomarker for a more detailed patient stratification in prospective clinical trials, and should be implemented into clinical routine if further validated. Citation Format: Nic G. Reitsam, Kelly Offermanns, Bianca Grosser, Jessica Zimmermann, Colinda Simons, Jakob N. Kather, Piet A. van den Brandt, Bruno Märkl, Heike I. Grabsch. Presence of Stroma AReactive Invasion Front Areas (SARIFA) - a potential novel histopathological tool for therapy response prediction in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6403.

Converging deep learning and human-observed tumor-adipocyte interaction as a biomarker in colorectal cancer

Characterization of the Fatty Acid Metabolism in Colorectal Cancer to Guide Clinical Therapy

The SARIFA biomarker in the context of basic research of lipid-driven cancers

Deep Learning Analysis of the Adipose Tissue and the Prediction of Prognosis in Colorectal Cancer.

Abstract 6403: Presence of Stroma AReactive Invasion Front Areas (SARIFA) - a potential novel histopathological tool for therapy response prediction in colorectal cancer

Circulating Bacterial DNA As a Tool Towards Noninvasive Biomarkers for Colorectal Adenocarcinoma and Adenoma.

Towards Non-Invasive Biomarkers in Colorectal Cancer Management: A Study on Integrating Radiomics and Deep Learning-Based Image Processing for Tumor-Stroma Interaction

Spatial characterization and stratification of colorectal adenomas by deep visual proteomics

Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas.

Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research

Identification of Adipocyte Infiltration-Related Gene Subtypes for Predicting Colorectal Cancer Prognosis and Responses of Immunotherapy/chemotherapy

Adipocytes impact on gastric cancer progression: Prognostic insights and molecular features

Exploring prognostic biomarkers in pathological images of colorectal cancer patients via deep learning

[SARIFA-a new multi-entity biomarker]

Deep learning in cancer pathology: a new generation of clinical biomarkers

Deep learning-based morphological feature analysis and the prognostic association study in colon adenocarcinoma histopathological images

Novel digital tissue phenotypic signatures of distant metastasis in colorectal cancer

The Radiogenomic Landscape of Clear Cell Renal Cell Carcinoma: Insights into Lipid Metabolism through Evaluation of ADFP Expression

Identification of novel diagnostic biomarkers associated with liver metastasis in colon adenocarcinoma by machine learning

A computed tomography-based multitask deep learning model for predicting tumour stroma ratio and treatment outcomes in patients with colorectal cancer: a multicentre cohort study

Merging metabolic modeling and imaging for screening therapeutic targets in colorectal cancer